Get the Daily Brief
Latest Biotech News
Rapport Therapeutics’ Seizure Drug RAP-219 Delivers Strong Phase 2 Results, Stock Triples
Rapport Therapeutics reported robust Phase 2 data for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator for drug-resistant focal onset seizures. The open-label study demonstrated a...
BioNTech and Bristol Myers Tout Promising PD-L1xVEGF Bispecific Data in Small Cell Lung Cancer
BioNTech and Bristol Myers Squibb unveiled the first global data for their PD-L1xVEGF bispecific antibody in combination with chemotherapy for small cell lung cancer. Mid-stage results...
Dianthus Therapeutics Reports Positive Phase 2 Data in Myasthenia Gravis, Sets Stage for Phase 3
Dianthus Therapeutics disclosed successful Phase 2 trial outcomes for claseprubart, a selective complement inhibitor targeting generalized myasthenia gravis. The antibody met multiple efficacy...
Epigenic Therapeutics Locks $60M Series B to Advance CRISPR-Based Gene Therapies
China’s Epigenic Therapeutics secured $60 million in Series B financing to propel clinical development of its lead gene therapy candidates EPI-003, targeting chronic hepatitis B, and EPI-001 for...
NRG Therapeutics Raises $67M to Propel Mitochondrial-Targeting Drugs for Neurodegeneration
UK-based NRG Therapeutics secured £50 million ($67 million) in an oversubscribed Series B round to advance its small-molecule regulators of the mitochondrial permeability transition pore (mPTP)...
Advances in AI and Data Integration Transform Bioprocessing and Drug Discovery
Artificial intelligence is rapidly reshaping biotech industries, from drug discovery to bioprocess manufacturing. A bibliometric study uncovered exponential growth in AI-related biotech...
Cancer Metabolism: Alternative Fuel Pathways and Novel Targeted Therapies Unveiled
Recent research from the Van Andel Institute revealed that cancer cells metabolize ketones via a non-canonical route to produce acetyl-CoA, implicating metabolic flexibility in tumor...
Julius Clinical Expands Footprint into Spain and Germany to Boost Global Trial Capabilities
Julius Clinical strategically launched new operations in Spain and Germany, aiming to enhance regulatory expertise and access to patients in key European markets. The Netherlands-based CRO cites...
Rapport Therapeutics' Seizure Drug Surges Amid Phase 2 Trial Win
Rapport Therapeutics reported striking Phase 2 data for its experimental epilepsy drug RAP-219, showing a median 78% reduction in seizure frequency across 30 patients. The open-label trial used...
Small Cell Lung Cancer Therapy Shows Mixed Phase 3 Results
Summit Therapeutics and partners presented updated data from the Phase 3 Harmoni trial evaluating ivonescimab combined with chemotherapy in advanced lung cancer. While early results from patients...
Emerging Therapies Advance Non-Small Cell Lung Cancer Care
Recent large-scale trials disclosed at the 2025 IASLC World Conference on Lung Cancer demonstrate significant improvements in NSCLC therapy. Aumolertinib combined with chemotherapy showed superior...
Dianthus Therapeutics Advances Myasthenia Gravis Treatment with Phase 2 Success
Dianthus Therapeutics announced positive Phase 2 data for its selective complement inhibitor, claseprubart, targeting generalized myasthenia gravis (gMG). The antibody met multiple efficacy...
FDA Advances Gene-Edited Pig Kidney Trials for Transplantation
The Food and Drug Administration has greenlighted clinical trials for transplantation of gene-edited pig kidneys into humans, marking a major milestone in xenotransplantation research. These...
RedC Biotech Develops Lab-Grown Universal Blood Supply
Israeli startup RedC Biotech is pioneering large-scale production of universal red blood cells derived from stem cells to alleviate global blood shortages. Utilizing bioreactors capable of...
Parkinson’s and ALS Targeting Mitochondrial Therapy Raises $67 Million
NRG Therapeutics secured $67 million in a funding round featuring Merck KGaA and Novartis venture arms, supporting development of its mitochondrial-targeted therapies for neurodegenerative...
Pfizer and BioNTech Report Updated COVID-19 Booster Antibody Data
Pfizer and BioNTech presented new data demonstrating that their updated COVID-19 vaccine booster induces increased neutralizing antibodies against circulating SARS-CoV-2 strains. This evidence...
Takeda and Alkermes Advance Orexin Agonists in Narcolepsy Market Race
Takeda and Alkermes disclosed encouraging Phase 3 and Phase 2 data for their orexin receptor 2-selective agonists, oveporexton and alixorexton, respectively, in treating narcolepsy type 1. Both...
Ionis Pharmaceuticals Surges on Positive Phase III Olezarsen Data
Ionis Pharmaceuticals shares surged 42% after reporting positive results from two pivotal Phase III trials evaluating olezarsen for severe hypertriglyceridemia. The antisense oligonucleotide...
RedC Biotech's Stem Cell Lab-Grown Blood: Potential to Save 2 Million Lives
Israeli startup RedC Biotech is pioneering the large-scale production of lab-grown red blood cells derived from stem cells, aiming to address global blood shortages that cause millions of deaths...
Breakthrough ADC Therapies Show Promise in Lung Cancer Trials
Recent clinical developments in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) reveal promising advances in antibody-drug conjugates (ADCs) and targeted therapies. At the...